Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Sebastiano Buti, Alessandro Leonetti, Alice Dallatomasina & Melissa Bersanelli. (2016) Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evidence 11, pages 23-36.
Read now
Read now
Wan-Xiang Zheng, Fei Yan, Qin Xue, Guo-Jun Wu, Wei-Jun Qin, Fu-Li Wang, Jun Qin, Chun-Juan Tian & Jian-Lin Yuan. (2015) Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib. OncoTargets and Therapy 8, pages 2081-2088.
Read now
Read now
Linda Cerbone, Federica Recine & Cora N Sternberg. (2014) Pharmacotherapy options for advanced renal cell carcinoma. Expert Opinion on Orphan Drugs 2:7, pages 643-652.
Read now
Read now
Camillo Porta, Roberto Sabbatini, Giuseppe Procopio, Chiara Paglino, Enzo Galligioni & Cinzia Ortega. (2012) Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Review of Anticancer Therapy 12:12, pages 1571-1577.
Read now
Read now
Ramy F. Youssef, Nicholas G. Cost, Oussama M. Darwish & Vitaly Margulis. (2012) Prognostic markers in renal cell carcinoma: A focus on the ‘mammalian target of rapamycin’ pathway. Arab Journal of Urology 10:2, pages 110-117.
Read now
Read now
Dylan T Jones & Adrian L Harris. (2012) Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. Expert Opinion on Therapeutic Targets 16:5, pages 463-480.
Read now
Read now
Elaine Cristina Lima de Souza, Andrea Claudia Freitas Ferreira & Denise Pires de Carvalho. (2011) The mTOR protein as a target in thyroid cancer. Expert Opinion on Therapeutic Targets 15:9, pages 1099-1112.
Read now
Read now
Piotr J Wysocki & Bogna Wierusz-Wysocka. (2010) Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Review of Molecular Diagnostics 10:4, pages 509-519.
Read now
Read now
Articles from other publishers (44)
Shu-Chi Tseng, Ho Yun Lee & Mizuki Nishino. (2022) Imaging of Drug-Related Pneumonitis in Oncology. Seminars in Respiratory and Critical Care Medicine 43:06, pages 887-898.
Crossref
Crossref
Qianmiao Wu, Huaijun Tu & Jian Li. (2022) Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Kerem Taken, Rahmi Aslan, Recep Eryilmaz, Hamit Hakan Alp, Zübeyir Huyut & Muhammet İrfan Dönmez. (2021) Serum irisin is a novel biomarker for bladder cancer detection. International Urology and Nephrology 54:1, pages 55-61.
Crossref
Crossref
Hyo Jae Shin, Kyung Jin Lee & Minchan Gil. (2021) Multiomic Analysis of Cereblon Expression and Its Prognostic Value in Kidney Renal Clear Cell Carcinoma, Lung Adenocarcinoma, and Skin Cutaneous Melanoma. Journal of Personalized Medicine 11:4, pages 263.
Crossref
Crossref
Esra Küpeli Akkol, Fatma Tuğçe Gürağaç Dereli, Eduardo Sobarzo-Sánchez & Haroon Khan. (2020) Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions. Current Topics in Medicinal Chemistry 20:20, pages 1772-1790.
Crossref
Crossref
Murat Sevmis, Sinasi Sevmis, Sema Aktas, Mansur Khalilov & Mehmet Emin Demir. (2020) Kidney Transplantation From Donors with Resectable Renal Cell Carcinoma: Two Case Reports. Transplantation Proceedings 52:3, pages 737-739.
Crossref
Crossref
Yongchang Lai, Tao Zeng, Xiongfa Liang, Weizou Wu, Fangling Zhong & Wenqi Wu. (2019) Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell International 19:1.
Crossref
Crossref
Wolfgang Eberhardt, Usman Nasrullah & Josef Pfeilschifter. (2018) Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors. Cellular Signalling 52, pages 1-11.
Crossref
Crossref
Aaron L. Brown, Maurice B. Fluitt & Carolyn M. Ecelbarger. (2018) Mechanistic target of rapamycin: integrating growth factor and nutrient signaling in the collecting duct. American Journal of Physiology-Renal Physiology 315:3, pages F413-F416.
Crossref
Crossref
Eva Juengel, Ramin Najafi, Jochen Rutz, Sebastian Maxeiner, Jasmina Makarevic, Frederik Roos, Igor Tsaur, Axel Haferkamp & Roman A. Blaheta. (2017) HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells. Oncotarget 8:66, pages 110016-110028.
Crossref
Crossref
Mamta Singla & Shalmoli Bhattacharyya. (2017) Autophagy as a potential therapeutic target during epithelial to mesenchymal transition in renal cell carcinoma: An in vitro study. Biomedicine & Pharmacotherapy 94, pages 332-340.
Crossref
Crossref
Sheng-Wen Wu, Pei-Ni Chen, Chin-Yin Lin, Yih-Shou Hsieh & Horng-Rong Chang. (2017) Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo. Environmental Toxicology 32:7, pages 1888-1898.
Crossref
Crossref
Sung Yoon LimMyung Gyu KimKwon Tae ParkCheol Woong Jung. (2017)
Experiences of renal transplants from donors with renal cell carcinoma after
ex vivo
partial nephrectomy
. Annals of Surgical Treatment and Research 92:5, pages 361.
Crossref
Crossref
Bo Sun, Liwei Chen, Hui Fu, Lin Guo, Hua Guo & Ning Zhang. (2015) Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma. Tumor Biology 37:4, pages 4457-4466.
Crossref
Crossref
Jinxia Ao, Chengjie Wei, Yu Si, Chaochao Luo, Wei Lv, Ye Lin, Yingjun Cui & Xuejun Gao. (2015) Tudor-SN Regulates Milk Synthesis and Proliferation of Bovine Mammary Epithelial Cells. International Journal of Molecular Sciences 16:12, pages 29936-29947.
Crossref
Crossref
L. Bodnar, R. Stec, S. Cierniak, A. Synowiec, G. Wcisło, M. Jesiotr, R. Koktysz, W. Kozłowski & C. Szczylik. (2015) Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. Annals of Oncology 26:7, pages 1385-1389.
Crossref
Crossref
Anna Sebestyén, Ágnes Márk, Melinda Hajdu, Noémi Nagy, Anna Molnár, Gyula Végső, Gábor Barna & László Kopper. (2015) Rapamycin can restore the negative regulatory function of transforming growth factor beta 1 in high grade lymphomas. Cytokine 73:2, pages 219-224.
Crossref
Crossref
Szu-Ying Wu, Ping-Jyun Sung, Ya-Ling Chang, Shiow-Lin Pan & Che-Ming Teng. (2015) Heteronemin, a Spongean Sesterterpene, Induces Cell Apoptosis and Autophagy in Human Renal Carcinoma Cells. BioMed Research International 2015, pages 1-13.
Crossref
Crossref
Nan Wang, Ruijuan Wu, Xiaoheng Cheng, Jin Jin, Zongchao Jia & Jimin Zheng. (2014) New insights into mTOR structure and regulation. Chinese Science Bulletin 59:24, pages 2927-2935.
Crossref
Crossref
Matthias A. Karajannis, Geneviève Legault, Mari Hagiwara, Filippo G. Giancotti, Alexander Filatov, Anna Derman, Tsivia Hochman, Judith D. Goldberg, Emilio Vega, Jeffrey H. Wisoff, John G. Golfinos, Amanda Merkelson, J. Thomas Roland & Jeffrey C. Allen. (2014) Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology 16:2, pages 292-297.
Crossref
Crossref
Pawel Sadlecki, Magdalena Bodnar, Marek Grabiec, Andrzej Marszalek, Pawel Walentowicz, Alina Sokup, Jolanta Zegarska & Małgorzata Walentowicz-Sadlecka. (2014)
The Role of Hypoxia-Inducible Factor-1
α
, Glucose Transporter-1, (GLUT-1) and Carbon Anhydrase IX in Endometrial Cancer Patients
. BioMed Research International 2014, pages 1-11.
Crossref
Crossref
Hua Wei, Hung-Lung Ke, Jie Lin, Sanjay Shete, Christopher G. Wood & Michelle A.T. Hildebrandt. (2014) MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk. Molecular Carcinogenesis 53:1, pages 1-7.
Crossref
Crossref
Hongyan Li, Xuefei Jin, Zhuo Zhang, Yuanyuan Xing & Xiangbo Kong. (2012) Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP‐BEZ235 in renal cell carcinoma cells. Cell Biochemistry and Function 31:5, pages 427-433.
Crossref
Crossref
Ming Xu, Guoquan Tao, Meiyun Kang, Yan Gao, Haixia Zhu, Weida Gong, Meilin Wang, Dongmei Wu, Zhengdong Zhang & Qinghong Zhao. (2013) A Polymorphism (rs2295080) in mTOR Promoter Region and Its Association with Gastric Cancer in a Chinese Population. PLoS ONE 8:3, pages e60080.
Crossref
Crossref
Hana Totary-Jain, Despina Sanoudou, Iddo Z. Ben-Dov, Cula N. Dautriche, Paolo Guarnieri, Steven O. Marx, Thomas Tuschl & Andrew R. Marks. (2013) Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin. Journal of Biological Chemistry 288:9, pages 6034-6044.
Crossref
Crossref
Agnes Maj-Hes, Jacques Medioni, Florian Scotte, Manuela Schmidinger, Gero Kramer, Pierre Combe, Yohan Gornadha, Reza Elaidi & Stéphane Oudard. (2013) Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy. Oncology 85:1, pages 8-13.
Crossref
Crossref
Michio Yoshimura, Satoshi Itasaka, Hiroshi Harada & Masahiro Hiraoka. (2013) Microenvironment and Radiation Therapy. BioMed Research International 2013, pages 1-13.
Crossref
Crossref
Linda Cerbone & Cora N. Sternberg. 2013. Renal Cancer. Renal Cancer
335
347
.
Eva Juengel, Anna Dauselt, Jasmina Makarević, Christoph Wiesner, Igor Tsaur, Georg Bartsch, Axel Haferkamp & Roman A. Blaheta. (2012) Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Letters 324:1, pages 83-90.
Crossref
Crossref
L. V. Klotz, M. E. Eichhorn, B. Schwarz, H. Seeliger, M. K. Angele, K.-W. Jauch & Christiane J. Bruns. (2012) Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbeck's Archives of Surgery 397:4, pages 569-578.
Crossref
Crossref
Leigh Ellis, Preeti Shah, Hans Hammers, Kristin Lehet, Paula Sotomayor, Gissou Azabdaftari, Mukund Seshadri & Roberto Pili. (2012) Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma. Molecular Cancer Therapeutics 11:2, pages 383-392.
Crossref
Crossref
Cinzia Ortega, Camillo Porta, Manuela Racca & Filippo Russo. 2012. Imaging Tumor Response to Therapy. Imaging Tumor Response to Therapy
61
75
.
W. Kimryn Rathmell. 2012. Renal Cell Carcinoma. Renal Cell Carcinoma
49
68
.
David Nicol & Shiro Fujita. (2011) Kidneys from patients with small renal tumours used for transplantation. Current Opinion in Urology 21:5, pages 380-385.
Crossref
Crossref
Mohammad Athar & Levy Kopelovich. (2011) Rapamycin and mTORC1 Inhibition in the Mouse: Skin Cancer Prevention. Cancer Prevention Research 4:7, pages 957-961.
Crossref
Crossref
David S. Finley, Allan J. Pantuck & Arie S. Belldegrun. (2011) Tumor Biology and Prognostic Factors in Renal Cell Carcinoma. The Oncologist 16:S2, pages 4-13.
Crossref
Crossref
Guanyu Wang. (2010) Singularity analysis of the AKT signaling pathway reveals connections between cancer and metabolic diseases. Physical Biology 7:4, pages 046015.
Crossref
Crossref
Nicole A. Johnson, Bing-Hung Chen, Shian-Ying Sung, Chia-Hui Liao, Wan-Chi Hsiao, Leland W. K. Chung & Chia-Ling Hsieh. (2010) A novel targeting modality for renal cell carcinoma: human osteocalcin promoter-mediated gene therapy synergistically induced by vitamin C and vitamin D3. The Journal of Gene Medicine 12:11, pages 892-903.
Crossref
Crossref
Tijs Claessens, Sherry A. Weppler, Michel van Geel, David Creytens, Maaike Vreeburg, Bradley Wouters & Maurice A. M. van Steensel. (2010) Neuroendocrine carcinoma in a patient with Birt–Hogg–Dubé syndrome. Nature Reviews Urology 7:10, pages 583-587.
Crossref
Crossref
Thomas Storz, Jianxin Gu, Bogdan Wilk & Eric Olsen. (2010) Regioselective lipase-catalyzed acylation of 41-desmethoxy-rapamycin without vinyl esters. Tetrahedron Letters 51:42, pages 5511-5515.
Crossref
Crossref
Chao-Yuan Huang, Jeff Yi-Fu Chen, Jia-En Wu, Yeong-Shiau Pu, Guang-Yaw Liu, Min-Hsiung Pan, Ying-Tang Huang, A-Mei Huang, Chi-Ching Hwang, Shu-Ju Chung & Tzyh-Chyuan Hour. (2010) Ling-Zhi Polysaccharides Potentiate Cytotoxic Effects of Anticancer Drugs against Drug-Resistant Urothelial Carcinoma Cells. Journal of Agricultural and Food Chemistry 58:15, pages 8798-8805.
Crossref
Crossref
Melissa C. Paoloni, Christina Mazcko, Elizabeth Fox, Timothy Fan, Susan Lana, William Kisseberth, David M. Vail, Kaylee Nuckolls, Tanasa Osborne, Samuel Yalkowsy, Daniel Gustafson, Yunkai Yu, Liang Cao & Chand Khanna. (2010) Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs. PLoS ONE 5:6, pages e11013.
Crossref
Crossref
Serafim Kiriakidis & Ewa M. Paleolog. 2011. Therapeutic Angiogenesis for Vascular Diseases. Therapeutic Angiogenesis for Vascular Diseases
361
382
.
Robert Y. Osamura. (2009) Roles of pathologists in molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine 13:11-12, pages 4286-4290.
Crossref
Crossref